Kiora Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.8M
- Price
- $2.66
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.53%
- Volume
- 16.4K
About
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Quick stats
Shares outstanding4.4M
Computed float4.3M
Float / shares96.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001372514
Websitehttps://www.kiorapharma.com
AI Summary
AI-generated1/10
standardbullishpartnership
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Kiora Pharmaceuticals licensed the South Korean development and commercialization rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation (CKD), securing a $1 million upfront payment plus milestone and royalty potential.
This deal completes Kiora's global partnering network for KIO-301, covering major markets including the U.S., Europe, Japan, and China, with CKD now responsible for the remaining key territory.
The partners intend to coordinate a single global Phase 3 clinical trial for retinitis pigmentosa, while Kiora shifts internal resources toward advancing KIO-104 for retinal inflammation.